#China #Leads Biolabs #Nanjing #cancer therapy #Opamtistomig

Leads Biolabs Secures Approval for Opamtistomig in Advanced EP-NEC Treatment

In a remarkable advancement for cancer therapeutics, Nanjing Leads Biolabs Co., Ltd. has recently announced that its novel bispecific antibody, Opamtistomig (LBL-024), has received pivotal Phase III approval from China’s National Medical Products Administration (NMPA). This groundbreaking decision signifies a major leap in treatment options for patients suffering from advanced extrapulmonary neuroendocrine carcinoma (EP-NEC), a particularly aggressive form of cancer characterized by its immunologically cold nature.

Prior to this approval, Opamtistomig had already demonstrated promising potential as a treatment for EP-NEC within previous clinical trials. Initially approved for a pivotal single-arm registration trial aimed at patients with late-stage disease, the new Phase III approval expands the therapy's application into the first-line treatment category, where there is a significant existing need. The randomized, double-blind, multicenter study will be overseen by prominent oncologist, Professor Lin Shen, from Peking University Cancer Hospital, emphasizing the collaborative effort being put into validating this innovative treatment.

Expanding Opportunities in Cancer Treatment

The pivotal Phase III study's approval only adds to the excitement surrounding Opamtistomig, which has shown favorable safety and efficacy profiles in initial trials. As the standard of care for advanced EP-NEC currently relies on platinum-based chemotherapy—offering an objective response rate (ORR) of merely 30%-50% and a median overall survival (mOS) of around one year—the entrance of Opamtistomig into the treatment landscape represents a potential game-changer. The complete results of the Phase Ib/II proof-of-concept study are set to be unveiled at the 2026 ESMO Congress, further illuminating the therapeutic promise this candidate holds.

In a wider context, Leads Biolabs is not resting on their laurels. The company aims to submit a Biologics License Application (BLA) in Q3 2026 to address treatment needs for advanced EP-NEC in the third-line or later settings. Alongside this submission, Leads Biolabs is actively conducting various proof-of-concept studies and preparing to launch at least two additional Phase III trials. These initiatives will examine Opamtistomig's efficacy across a broader spectrum of solid tumor indications, such as small cell lung cancer (SCLC), biliary tract cancer (BTC), and even first-line non-small cell lung cancer (NSCLC).

A Closer Look at Opamtistomig

Developed through Leads Biolabs' proprietary X-Body bispecific platform, Opamtistomig presents a dual mechanism of action by targeting both PD-L1 and the co-stimulatory receptor 4-1BB. This innovative approach facilitates the blocking of immune suppression while simultaneously activating robust anti-tumor immune responses. Notably, early indications suggest that Opamtistomig may possess first- or best-in-class potential across various cancer types. Its broad-spectrum anti-cancer capabilities have already led to the drug receiving Breakthrough Therapy Designation (BTD) and Orphan Drug Designation (ODD) from both China’s NMPA and the U.S. FDA.

In addition, Opamtistomig has proven its versatility in trials across 13 solid tumor indications. These include high-priority areas such as triple-negative breast cancer, gastric cancer, and esophageal squamous cell carcinoma—criminally underserved domains in cancer treatment reflecting urgent unmet medical needs.

Pioneering Changes in Cancer Care

Dr. Charles Cai, Leads Biolabs' Chief Medical Officer, expressed optimism regarding the clinical implications of Opamtistomig. Highlighting the regulatory agency's keen awareness of unmet clinical needs, Cai emphasized the importance of strong regulatory feedback in accelerating the pivotal Phase III protocol next steps. He stated, "We look forward to validating its potential to extend patient survival through a high-quality trial, bringing this innovative therapy to EP-NEC patients as soon as possible."

As the landscape of oncology continues to evolve, the approval and forthcoming clinical trials of Opamtistomig stand as a testament to the advancements being made in cancer therapeutics, potentially reshaping the way advanced neuroendocrine carcinoma—and other malignancies—are treated. The dedication and innovative spirit at Leads Biolabs herald significant changes ahead for patients facing grave prognoses in their battle against cancer.